Flexion's OA Knee Injection On Track For H2 Filing

Burlington, Mass.-based Flexion Therapeutics Inc.'s long-acting steroid injection Zilretta has been associated with statistically significant improvements in pain relief in a pivotal Phase III study in patients with knee osteoarthritis, countering disappointing results from a Phase IIb study reported last year and keeping the product in line for a US NDA submission in the second half on 2016.

Burlington, Mass.-based Flexion Therapeutics Inc.'s long-acting steroid injection Zilretta has been associated with statistically significant improvements in pain relief in a pivotal Phase III study in patients with knee osteoarthritis, countering disappointing results from a Phase IIb study reported last year and keeping the product in line for a US NDA submission in the second half on 2016.

Zilretta (FX006; triamcinolone acetonide) is believed to be the leading intra-articular, sustained-release, non-opioid treatment for patients with moderate to severe...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Musculoskeletal

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By 

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By 

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

 
• By 

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.

Regenxbio Rises After Duchenne Update And Sarepta Safety Scare

 

Encouraging results in younger children with Duchenne is keeping Regenxbio on track for a potential mid-2026 filing for its gene therapy, RGX-202.

More from Therapy Areas

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By 

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.